Cell-free porcine corneal grafts are showing early promise as an alternative to human donor corneas, which are in critically short supply. In a small study of 27 patients, the grafts improved vision, increased transparency, and integrated structurally within months. Researchers say larger, longer-term studies are still needed before these xenografts become routine clinical practice.
Corneal transplantation is one of the most common tissue transplant procedures performed globally, yet donor corneas remain persistently scarce. In Germany alone, over 4,600 patients were on the waiting list for a corneal transplant at the end of 2020 — with waits stretching up to a year. To bridge this gap, researchers are turning to acellular porcine corneal stroma (APCS): grafts derived from pig corneas that have been stripped of their cells to reduce immune rejection while preserving the structural collagen scaffold.
Early results are encouraging. In a prospective case series of 27 patients treated for infectious keratitis, APCS grafts led to improved best-corrected visual acuity, increased graft transparency, and full corneal re-epithelialization within just one week post-surgery. By 3–6 months, imaging confirmed that the recipient's own cells had begun repopulating the graft — a sign of true structural integration.
Key Takeaways:
Why it matters: With millions of patients worldwide lacking access to donor corneas, xenograft solutions like APCS could dramatically expand treatment options — but only if safety and durability can be confirmed at scale.
